On the CGI-I scale , the analysis revealed that MPH was more effective than ATX and GXR .
For any adverse events , RBX ( 89 % ) was the safest alternative .
Network meta- analysis offered a broader overview on the available treatments for ADHD , especially for safety issues , and contributes towards evidence gathering and clinical practice decisions .
The aim of this study is to gather evidence of head-to-head double-blind r and omized-controlled trials on the efficacy and safety of available treatments for attention deficit hyperactivity disorder ( ADHD ) in children and adolescents .
Effects of atomoxetine and methylphenidate on sleep in children with ADHD.
STUDY OBJECTIVES This study compared the effects of atomoxetine and methylpheni date on the sleep of children with attention-deficit/hyperactivity disorder ( ADHD ) . This study also compared the efficacy of these medications for treating ADHD in these children . DESIGN R and omized , double-blind , crossover trial . SETTING Two sleep disorders centers in the United States ; 1 in a private- practice setting and 1 in a hospital setting . PATIENTS 85 children diagnosed with ADHD . INTERVENTIONS Twice-daily atomoxetine and thrice-daily methylpheni date , each for approximately 7 weeks . MEASUREMENTS AND RESULTS Relative to baseline , the actigraphy data indicated that methylpheni date increased sleep-onset latency significantly more than did atomoxetine ( 39.2 vs 12.1 minutes , p < .001 ) . These results were consistent with the polysomnography data . Child diaries indicated that it was easier to get up in the morning , it took less time to fall asleep , and the children slept better with atomoxetine , compared with methylpheni date . Parents reported that it was less difficult getting their children up and getting them ready in the morning and that the children were less irritable , had less difficulty getting ready for bed , and had less difficulty falling asleep with atomoxetine , compared with methylpheni date . There were no significant differences between medications using the main measures of efficacy for ADHD treatment . Atomoxetine was superior on some secondary ADHD treatment-efficacy measures , based on parent reports . The only significant differences in treatment-emergent adverse events were greater incidence of decreased appetite and greater incidence of insomnia with methylpheni date . CONCLUSIONS Patients receiving twice-daily atomoxetine had shorter sleep-onset latencies , relative to thrice-daily methylpheni date , based on objective actigraphy and polysomnography data . Although both medications decreased nighttime awakenings , the decrease was greater for methylpheni date
On the CGI-I scale , the analysis revealed that MPH was more effective than ATX and GXR .
For any adverse events , RBX ( 89 % ) was the safest alternative .
Network meta- analysis offered a broader overview on the available treatments for ADHD , especially for safety issues , and contributes towards evidence gathering and clinical practice decisions .
The aim of this study is to gather evidence of head-to-head double-blind r and omized-controlled trials on the efficacy and safety of available treatments for attention deficit hyperactivity disorder ( ADHD ) in children and adolescents .